Do drugmakers “revenue target”? Evidence from the differential timing of biosimilar entry across markets

If your institution is a member, please log into Policy Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Accessing this content requires a membership

If your institution is a member, please log into Policy Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.